CEO, AM-Pharma Erik brings over 25 years’ experience and serves as CEO at AM-Pharma since 2011. Erik is Chairman of Step Pharma and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead
Fellow in Cardiology, Research Associate Giuseppina has a longstanding research experience in the role of CD31 in vascular biology and immunology. She works both as a cardiologist and a research scientist at the University Hospital Bichat, in Paris. Giuseppina completed her medical studies at the Catholic University of Rome, obtained
Scientific Advisor, Advent Life Sciences Fraser is a neuropharmacologist with almost 30 years of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation, gastrointestinal and dermatology. He has a wide C-suite experience in multiple biotech startups and held leadership roles at Shire, AstraZeneca,
Investment Director, Life Sciences, Bpifrance Investissements Since 2014 at Bpifrance Investissements, Benoit has been involved in a dozen investment deals and current board member positions include Alentis, Dynacure, Igyxos, Meiogenix and BrainEver. Prior to this, he gained experience in various biotech roles, co-discovered a vaccine candidate, and developed an antibody
Managing Partner, Pureos Bioventures Over the last two decades, Dr. Breiner has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich, and a researcher at the Swiss Federal Institute of Technology in Zurich and
Chairman and Managing Partner, AdBio Partners Alain brings over 30 years of experience in life sciences and finance. He started his career as a General Practitioner (GP) and then spent ten years in biotechnology drug development and regulatory strategy as vice president of Quintiles (IQVIA) Europe. Prior to joining VC firm Advent Life Sciences